Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACH-000143 have been identified as a novel agonist of the melatonin receptors MT1 and MT2.
説明 | ACH-000143 have been identified as a novel agonist of the melatonin receptors MT1 and MT2. |
ターゲット&IC50 | MT1:0.06 nM(EC50), MT2:0.32 nM(EC50) |
In vitro | ACH-000143 demonstrated subnanomolar potency at MT1/MT2 receptors, high oral bioavailability in rodents, peripherally preferred exposure, and excellent selectivity in a broad panel of targets. |
In vivo | Two-month oral administration of ACH-000143 in high-fat diet rats led to a reduction in body weight gain similar to dapagliflozin with superior results on hepatic steatosis and triglyceride levels. |
分子量 | 297.74 |
分子式 | C13H16ClN3O3 |
CAS No. | 2225836-30-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (201.52 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ACH-000143 2225836-30-4 GPCR/G Protein Neuroscience Melatonin Receptor MT Receptor ACH000143 HFD toxicity low steatosis Inhibitor ACH 000143 inhibit obese inhibitor